Quarterly report · Q2

Period2021-12-01 → 2022-05-31
Filed2022-07-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥3.9bn2021-12-01 → 2022-05-31Cons.Net sales
Revenue¥7.9bn2020-12-01 → 2021-11-30Cons.Net sales (5-year summary)
Revenue¥3.9bn2020-12-01 → 2021-05-31Cons.Net sales
Operating income¥226m2021-12-01 → 2022-05-31Cons.Operating income
Operating income¥270m2020-12-01 → 2021-05-31Cons.Operating income
Ordinary income¥235m2021-12-01 → 2022-05-31Cons.Ordinary income
Ordinary income¥386m2020-12-01 → 2021-11-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥273m2020-12-01 → 2021-05-31Cons.Ordinary income
Profit before tax¥234m2021-12-01 → 2022-05-31Cons.Income before income taxes
Profit before tax¥273m2020-12-01 → 2021-05-31Cons.Income before income taxes
Net income (owners)¥179m2021-12-01 → 2022-05-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥281m2020-12-01 → 2021-11-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥195m2020-12-01 → 2021-05-31Cons.Profit loss attributable to owners of parent
Net income¥179m2021-12-01 → 2022-05-31Cons.Profit loss
Net income¥195m2020-12-01 → 2021-05-31Cons.Profit loss
Total assets¥7.8bnat 2022-05-31Cons.Assets
Total assets¥7.9bnat 2021-11-30Cons.Assets
Total assets¥7.6bnat 2021-05-31Cons.Total assets (5-year summary)
Total liabilities¥5.4bnat 2022-05-31Cons.Liabilities
Total liabilities¥5.6bnat 2021-11-30Cons.Liabilities
Net assets / equity¥2.4bnat 2022-05-31Cons.Net assets
Net assets / equity¥2.3bnat 2021-11-30Cons.Net assets
Net assets / equity¥2.2bnat 2021-05-31Cons.Net assets (5-year summary)
Cash and deposits¥984mat 2022-05-31Cons.Cash and deposits
Cash and deposits¥1.3bnat 2021-11-30Cons.Cash and deposits
Cash & equivalents¥984mat 2022-05-31Cons.Cash and cash equivalents
Cash & equivalents¥1.3bnat 2021-11-30Cons.Cash and cash equivalents
Cash & equivalents¥1.1bnat 2021-05-31Cons.Cash and cash equivalents
Cash & equivalents¥883mat 2020-11-30dCons.Cash and cash equivalents
Operating cash flow−¥124m2021-12-01 → 2022-05-31Cons.Net cash provided by used in operating activities
Operating cash flow¥785m2020-12-01 → 2021-11-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥388m2020-12-01 → 2021-05-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥121m2021-12-01 → 2022-05-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥246m2020-12-01 → 2021-11-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥109m2020-12-01 → 2021-05-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥104m2021-12-01 → 2022-05-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥119m2020-12-01 → 2021-11-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥78m2020-12-01 → 2021-05-31Cons.Net cash provided by used in financing activities
EPS (basic)¥147.062021-12-01 → 2022-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥68.822022-03-01 → 2022-05-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥230.992020-12-01 → 2021-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥160.32020-12-01 → 2021-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥95.622021-03-01 → 2021-05-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio30.6%at 2022-05-31Cons.Equity to asset ratio (5-year summary)
Equity ratio28.5%at 2021-11-30Cons.Equity to asset ratio (5-year summary)
Equity ratio28.5%at 2021-05-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2021-12-01 → 2022-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2021-12-01 → 2022-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2021-12-01 → 2022-05-31¥211m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2021-12-01 → 2022-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2021-12-01 → 2022-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2021-12-01 → 2022-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2021-12-01 → 2022-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-12-01 → 2022-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-12-01 → 2022-05-31¥226m
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2020-12-01 → 2021-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2020-12-01 → 2021-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2020-12-01 → 2021-05-31¥255m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2020-12-01 → 2021-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2020-12-01 → 2021-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2020-12-01 → 2021-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2020-12-01 → 2021-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2020-12-01 → 2021-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2020-12-01 → 2021-05-31¥270m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 477
ItemContextValueUnit
Note on independent audit financial informationCurrentYTDDurationText · Plus
Quarterly consolidated balance sheet (text)CurrentYTDDurationText · Plus
Year to quarter end consolidated statement of income (text)CurrentYTDDurationText · Plus
Year to quarter end consolidated statement of comprehensive income (text)CurrentYTDDurationText · Plus
Quarterly consolidated statement of cash flows (text)CurrentYTDDurationText · Plus
Notes uncertainties of entitys ability to continue as going concern quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Notes changes in scope of consolidation or equity method (text)CurrentYTDDurationText · Plus
Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Notes additional information quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Major components of selling general and administrative expenses (text)CurrentYTDDurationText · Plus
Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text)CurrentYTDDurationText · Plus
Notes regarding dividend (text)Prior1YTDDurationText · Plus
Notes when there is significant changes in amounts of equity (text)Prior1YTDDurationText · Plus
Notes regarding dividend (text)CurrentYTDDurationText · Plus
Notes when there is significant changes in amounts of equity (text)CurrentYTDDurationText · Plus
Notes segment information etc quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Footnotes regarding segment information table (text)Prior1YTDDurationText · Plus
Information about impairment loss of non current assets or goodwill etc for each reportable segment (text)Prior1YTDDurationText · Plus
Footnotes regarding segment information table (text)CurrentYTDDurationText · Plus
Disclosure of changes etc in reportable segments (text)CurrentYTDDurationText · Plus
Information about impairment loss of non current assets or goodwill etc for each reportable segment (text)CurrentYTDDurationText · Plus
Notes revenue recognition quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Notes per share information quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Notes significant events after reporting period quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Other information consolidated financial statements etc (text)CurrentYTDDurationText · Plus
Information about company which provides guarantee to reporting company (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2021-11-30pass
balance sheet identityconsolidated 2022-05-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-11-30pass
statement vs summary · net assetsconsolidated 2022-05-31pass
statement vs summary · net income attributable to parentconsolidated 2020-12-01/2021-05-31pass
statement vs summary · net income attributable to parentconsolidated 2021-12-01/2022-05-31pass
statement vs summary · operating cash flowconsolidated 2020-12-01/2021-05-31pass
statement vs summary · operating cash flowconsolidated 2021-12-01/2022-05-31pass
statement vs summary · revenueconsolidated 2020-12-01/2021-05-31pass
statement vs summary · revenueconsolidated 2021-12-01/2022-05-31pass
statement vs summary · total assetsconsolidated 2021-11-30pass
statement vs summary · total assetsconsolidated 2022-05-31pass